Willis Investment Counsel Has $3.85 Million Stock Position in Medpace Holdings, Inc. $MEDP

Willis Investment Counsel lifted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 56.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,250 shares of the company’s stock after purchasing an additional 4,402 shares during the period. Willis Investment Counsel’s holdings in Medpace were worth $3,845,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Mawer Investment Management Ltd. bought a new stake in shares of Medpace in the first quarter valued at about $212,131,000. Vulcan Value Partners LLC raised its stake in Medpace by 221.6% in the 1st quarter. Vulcan Value Partners LLC now owns 325,916 shares of the company’s stock worth $99,159,000 after purchasing an additional 224,578 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in Medpace by 675.8% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 121,464 shares of the company’s stock valued at $37,009,000 after purchasing an additional 105,807 shares during the period. Invesco Ltd. grew its position in shares of Medpace by 9.4% during the 1st quarter. Invesco Ltd. now owns 1,186,768 shares of the company’s stock worth $361,596,000 after purchasing an additional 102,015 shares in the last quarter. Finally, Northern Trust Corp grew its position in shares of Medpace by 36.0% during the 1st quarter. Northern Trust Corp now owns 337,489 shares of the company’s stock worth $102,830,000 after purchasing an additional 89,347 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Medpace

In related news, President Jesse J. Geiger sold 21,503 shares of the firm’s stock in a transaction dated Wednesday, November 5th. The shares were sold at an average price of $595.66, for a total transaction of $12,808,476.98. Following the transaction, the president directly owned 15,000 shares of the company’s stock, valued at $8,934,900. This trade represents a 58.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Robert O. Kraft sold 6,472 shares of the company’s stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $591.85, for a total transaction of $3,830,453.20. Following the completion of the sale, the director directly owned 833 shares of the company’s stock, valued at $493,011.05. The trade was a 88.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 201,308 shares of company stock worth $114,534,479. 20.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

MEDP has been the topic of a number of recent research reports. BMO Capital Markets started coverage on Medpace in a research note on Thursday, November 13th. They set a “market perform” rating and a $600.00 price objective on the stock. Robert W. Baird set a $613.00 target price on Medpace in a report on Friday, October 24th. Truist Financial set a $555.00 price target on Medpace in a research note on Monday, October 27th. Rothschild & Co Redburn downgraded shares of Medpace from a “buy” rating to a “neutral” rating and increased their price objective for the stock from $342.00 to $474.00 in a research note on Wednesday, September 3rd. Finally, Barclays raised their target price on shares of Medpace from $425.00 to $485.00 and gave the company an “underweight” rating in a report on Friday, October 24th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, ten have given a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat.com, Medpace presently has a consensus rating of “Hold” and an average price target of $487.18.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $586.16 on Friday. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $625.00. The business’s 50 day simple moving average is $547.43 and its two-hundred day simple moving average is $430.70. The firm has a market cap of $16.51 billion, a P/E ratio of 40.99, a PEG ratio of 2.67 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm had revenue of $659.90 million during the quarter, compared to analysts’ expectations of $640.49 million. During the same period last year, the company earned $3.01 earnings per share. The business’s revenue was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, equities analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.